DVAX up +894.97% percent right now. $DVAX High is
Post# of 144509
Posted On: 11/10/2014 12:17:23 PM
DVAX up +894.97% percent right now. $DVAX High is at 16.40 and the Low 15.05 with current volume of 333,107.
Recent News posted below.
DVAX Dynavax Technologies Corp Recent Headline News
Dynavax's board authorises one-for-ten reverse common stock split
M2 - Mon Nov 10, 7:45AM CST
Dynavax Technologies (NASDAQ
VAX), a biopharmaceutical company, announced on Saturday that it has completed a one-for-ten reverse split of its common stock.
DVAX: 15.90 (+14.31)
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)
Marketwired - Mon Nov 10, 5:01AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine, has completed its first prespecified review and has recommended that the study continue unchanged.
DVAX: 15.90 (+14.31)
Dynavax Announces One-for-Ten Reverse Stock Split
Marketwired - Fri Nov 07, 4:05PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it had completed a one-for-ten reverse split of its common stock, effective as of 5:00 pm Eastern Time today. Beginning with the opening of trading on November 10, 2014 the Company's common stock will trade on the NASDAQ Capital Market on a split-adjusted basis.
DVAX: 15.90 (+14.31)
Dynavax Technologies misses 3Q profit forecasts
Automated Insights - Wed Nov 05, 5:18AM CST
BERKELEY, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Wednesday reported a loss of $29.8 million in its third quarter.
DVAX: 15.90 (+14.31)
Dynavax Reports Third Quarter 2014 Financial Results
Marketwired - Wed Nov 05, 5:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2014.
DVAX: 15.90 (+14.31)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
M2 - Fri Oct 31, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zmnrcn/global_pediatric) has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering. Pediatric vaccines are used for the immunization of children and adolescents against various infectious diseases, such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the US FDA, pediatric age ranges are classified as newborn, infant, child, and adolescent, ranging from birth to 21 years. However, the EMA classifies pediatric age range from birth to 18 years. The analysts forecast the Global Pediatric Vaccine market to grow at a CAGR of 10.25 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pediatric Vaccine market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various approved vaccines. The report, the Global Pediatric Vaccine Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pediatric Vaccine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Route of Administration 08. Market Segmentation by Product Type 09. Geographical Segmentation 10. Key Leading Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - AstraZeneca - Bavarian Nordic - Baxter - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Crucell - Dynavax Technologies - GlaxoSmithKline - Indian Immunologicals - Janssen - Kaketsuken - LG Life Sciences - Lupin - Merck - Mitsubishi Tanabe Pharma - Novartis - Nuron - Panacea Biotec - Pfizer - S K Chemicals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Takeda Pharmaceutical - Valeant Pharmaceuticals - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/zm..._pediatric
DVAX: 15.90 (+14.31), MRK: 58.75 (-0.59), GSK: 45.20 (+0.29), SVA: 5.23 (-0.06), NVS: 92.49 (+0.73)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 15.90 (+14.31), BIIB: 324.96 (+4.21), AMRN: 0.86 (-0.04), UTHR: 125.55 (+1.34), NLNK: 33.34 (+1.19)
Dynavax Technologies (DVAX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:05AM CDT
Dynavax Technologies (DVAX) Shares March Higher, Can It Continue?
DVAX: 15.90 (+14.31)
3 Stocks Under $10 Triggering Breakout Trades
at The Street - Fri Oct 24, 7:20AM CDT
These stocks trading for less than $10 a share are within range of triggering breakout trades.
DVAX: 15.90 (+14.31), PKT: 7.25 (+0.06), VHC: 5.78 (-0.05)
3 Beaten Down Biotech Stocks to Buy Now
George Budwell, The Motley Fool - Motley Fool - Thu Oct 23, 10:20AM CDT
Biotech stocks that crumble after a clinical or regulatory setback can turn out to be stellar long-term buys. Even so, it's critical to understand why the stock plunged in the first place, and how management plans on putting the company on track to...
DVAX: 15.90 (+14.31), CLVS: 58.52 (+0.21), CLDX: 14.36 (+0.94), AZN: 73.18 (+0.30), GSK: 45.20 (+0.29)
Dynavax Initiates Phase I/II Trial on Lymphoma Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:35PM CDT
Dynavax Technologies Corporation (DVAX) announced that it will initiate a phase I/II clinical trial, LYM-01, to assess the safety and preliminary efficacy of its pipeline candidate, SD-101.
MDVN: 110.37 (-2.40), DVAX: 15.90 (+14.31), PSTI: 2.67 (+0.01), GSK: 45.20 (+0.29)
Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma
Marketwired - Mon Oct 13, 5:00AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a phase 1/2 clinical trial to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor ("TLR"
9 agonist, in adults with untreated low-grade B-cell lymphoma. In this multicenter study (known as LYM-01), SD-101 is administered intratumorally in combination with localized low-dose radiation. The open-label, dose escalation and expansion design of LYM-01 is intended to accelerate dose optimization while simultaneously assessing the safety, tolerability and initial local and distant antitumor activity of SD-101.
DVAX: 15.90 (+14.31)
Dynavax reports departure of board member Dr Dino Dina
M2 - Wed Oct 08, 6:24AM CDT
Biopharmaceutical company Dynavax Technologies (NASDAQ VAX) revealed on Tuesday the resignation of Dr Dino Dina, MD from its board of directors.
DVAX: 15.90 (+14.31)
Hodgkin Lymphoma - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr6ljs/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics Companies Mentioned: - Bristol-Myers Squibb - Johnson & Johnson - Seattle Genetics - Merck & Co - Gamida Cell - Millennium Pharmaceuticals - Novartis - Ono Pharmaceutical - Sigma-Tau - Incyte - 4SC - Dynavax Technologies - Spectrum - Affimed - Actinium - Philogen - Constellation - Stemline - Syndax - Acetylon - Rhizen - Immune For more information visit http://www.researchandmarkets.com/research/vr...n_lymphoma
DVAX: 15.90 (+14.31), JNJ: 108.59 (+0.39), MRK: 58.77 (-0.57), BMY: 58.58 (+0.26), NVS: 92.48 (+0.72)
Dynavax Announces Resignation of Dino Dina From Board of Directors
Marketwire - Tue Oct 07, 3:00PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Dino Dina, M.D, has resigned from the Board of Directors. Dr. Dina was a director of the Company since 1997 and was the Company's Chief Executive Officer between 1998 and 2013.
DVAX: 15.90 (+14.31)
Dynavax (DVAX) Completes Enrolment for Study on Heplisav - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:00PM CDT
Dynavax Technologies Corporation (DVAX) announced that it completed the planned enrolment in the ongoing clinical trial, HBV-23, on experimental hepatitis B vaccine, Heplisav-B.
DVAX: 15.90 (+14.31), JAZZ: 171.91 (+1.11), GSK: 45.20 (+0.29), PCRX: 88.00 (+1.98)
Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
DVAX: 15.90 (+14.31), HSKA: 16.01 (+0.11), GILD: 108.21 (+1.76), ILMN: 188.95 (+2.60)
Dynavax concludes enrollment of Phase 3 Study of adult hepatitis B vaccine HEPLISAV-B
M2 - Mon Sep 22, 6:24AM CDT
Biopharmaceutical company Dynavax Technologies (NASDAQ VAX) said on Monday that it has completed the planned enrollment of more than 8,250 adults, including over 1,100 diabetic subjects, under its ongoing phase 3 clinical trial of HEPLISAV-B at 40 sites in the US.
DVAX: 15.90 (+14.31)
Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B(TM)
Marketwire - Mon Sep 22, 5:00AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced completion of planned enrollment in the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. More than 8,250 adults, including over 1,100 diabetic subjects, have been enrolled at 40 sites in the U.S.
DVAX: 15.90 (+14.31)
Analyst Scanner on Biotech Equities - Prana Biotechnology, CytRx, Insmed, Dynavax Technologies, and Vertex Pharma
PR Newswire - Thu Sep 11, 8:15AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.25, up 0.67%, with the index gaining 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), CytRx Corporation (NASDAQ: CYTR), Insmed Inc. (NASDAQ: INSM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research on these five companies can be accessed at:
DVAX: 15.90 (+14.31), INSM: 14.01 (-0.12), VRTX: 116.64 (+0.71), CYTR: 2.78 (-0.09), PRAN: 1.73 (-0.01)
Recent News posted below.
DVAX Dynavax Technologies Corp Recent Headline News
Dynavax's board authorises one-for-ten reverse common stock split
M2 - Mon Nov 10, 7:45AM CST
Dynavax Technologies (NASDAQ
VAX), a biopharmaceutical company, announced on Saturday that it has completed a one-for-ten reverse split of its common stock. DVAX: 15.90 (+14.31)
Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)
Marketwired - Mon Nov 10, 5:01AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the independent Data and Safety Monitoring Board (DSMB) charged with periodically reviewing safety data from the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine, has completed its first prespecified review and has recommended that the study continue unchanged.
DVAX: 15.90 (+14.31)
Dynavax Announces One-for-Ten Reverse Stock Split
Marketwired - Fri Nov 07, 4:05PM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it had completed a one-for-ten reverse split of its common stock, effective as of 5:00 pm Eastern Time today. Beginning with the opening of trading on November 10, 2014 the Company's common stock will trade on the NASDAQ Capital Market on a split-adjusted basis.
DVAX: 15.90 (+14.31)
Dynavax Technologies misses 3Q profit forecasts
Automated Insights - Wed Nov 05, 5:18AM CST
BERKELEY, Calif. (AP) _ Dynavax Technologies Corp. (DVAX) on Wednesday reported a loss of $29.8 million in its third quarter.
DVAX: 15.90 (+14.31)
Dynavax Reports Third Quarter 2014 Financial Results
Marketwired - Wed Nov 05, 5:00AM CST
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2014.
DVAX: 15.90 (+14.31)
Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi
M2 - Fri Oct 31, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zmnrcn/global_pediatric) has announced the addition of the "Global Pediatric Vaccine Market 2014-2018" report to their offering. Pediatric vaccines are used for the immunization of children and adolescents against various infectious diseases, such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases. According to the US FDA, pediatric age ranges are classified as newborn, infant, child, and adolescent, ranging from birth to 21 years. However, the EMA classifies pediatric age range from birth to 18 years. The analysts forecast the Global Pediatric Vaccine market to grow at a CAGR of 10.25 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pediatric Vaccine market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various approved vaccines. The report, the Global Pediatric Vaccine Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Pediatric Vaccine market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Route of Administration 08. Market Segmentation by Product Type 09. Geographical Segmentation 10. Key Leading Countries 11. Buying Criteria 12. Market Growth Drivers 13. Drivers and their Impact 14. Market Challenges 15. Impact of Drivers and Challenges 16. Market Trends 17. Trends and their Impact 18. Vendor Landscape 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - AstraZeneca - Bavarian Nordic - Baxter - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Crucell - Dynavax Technologies - GlaxoSmithKline - Indian Immunologicals - Janssen - Kaketsuken - LG Life Sciences - Lupin - Merck - Mitsubishi Tanabe Pharma - Novartis - Nuron - Panacea Biotec - Pfizer - S K Chemicals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Takeda Pharmaceutical - Valeant Pharmaceuticals - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/zm..._pediatric
DVAX: 15.90 (+14.31), MRK: 58.75 (-0.59), GSK: 45.20 (+0.29), SVA: 5.23 (-0.06), NVS: 92.49 (+0.73)
Market Movers - Biotech Stocks -- NewLink Genetics, Biogen Idec, United Therapeutics, Dynavax Technologies, and Amarin
PR Newswire - Wed Oct 29, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: NewLink Genetics Corporation (NASDAQ: NLNK), Biogen Idec Inc. (NASDAQ: BIIB), United Therapeutics Corporation (NASDAQ: UTHR), Dynavax Technologies Corporation (NASDAQ: DVAX), and Amarin Corporation PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 28, 2014, the NASDAQ Composite ended at 4,564.29, up 1.75%, the Dow Jones Industrial Average advanced 1.12%, to finish the day at 17,005.75, and the S&P 500 closed at 1,985.05, up 1.19%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 760.91, up 0.74%, with the index also advancing 6.21% in the previous three months. Register for your complimentary reports on these five stocks at:
DVAX: 15.90 (+14.31), BIIB: 324.96 (+4.21), AMRN: 0.86 (-0.04), UTHR: 125.55 (+1.34), NLNK: 33.34 (+1.19)
Dynavax Technologies (DVAX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:05AM CDT
Dynavax Technologies (DVAX) Shares March Higher, Can It Continue?
DVAX: 15.90 (+14.31)
3 Stocks Under $10 Triggering Breakout Trades
at The Street - Fri Oct 24, 7:20AM CDT
These stocks trading for less than $10 a share are within range of triggering breakout trades.
DVAX: 15.90 (+14.31), PKT: 7.25 (+0.06), VHC: 5.78 (-0.05)
3 Beaten Down Biotech Stocks to Buy Now
George Budwell, The Motley Fool - Motley Fool - Thu Oct 23, 10:20AM CDT
Biotech stocks that crumble after a clinical or regulatory setback can turn out to be stellar long-term buys. Even so, it's critical to understand why the stock plunged in the first place, and how management plans on putting the company on track to...
DVAX: 15.90 (+14.31), CLVS: 58.52 (+0.21), CLDX: 14.36 (+0.94), AZN: 73.18 (+0.30), GSK: 45.20 (+0.29)
Dynavax Initiates Phase I/II Trial on Lymphoma Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 3:35PM CDT
Dynavax Technologies Corporation (DVAX) announced that it will initiate a phase I/II clinical trial, LYM-01, to assess the safety and preliminary efficacy of its pipeline candidate, SD-101.
MDVN: 110.37 (-2.40), DVAX: 15.90 (+14.31), PSTI: 2.67 (+0.01), GSK: 45.20 (+0.29)
Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma
Marketwired - Mon Oct 13, 5:00AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced initiation of a phase 1/2 clinical trial to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor ("TLR"
9 agonist, in adults with untreated low-grade B-cell lymphoma. In this multicenter study (known as LYM-01), SD-101 is administered intratumorally in combination with localized low-dose radiation. The open-label, dose escalation and expansion design of LYM-01 is intended to accelerate dose optimization while simultaneously assessing the safety, tolerability and initial local and distant antitumor activity of SD-101. DVAX: 15.90 (+14.31)
Dynavax reports departure of board member Dr Dino Dina
M2 - Wed Oct 08, 6:24AM CDT
Biopharmaceutical company Dynavax Technologies (NASDAQ
VAX) revealed on Tuesday the resignation of Dr Dino Dina, MD from its board of directors. DVAX: 15.90 (+14.31)
Hodgkin Lymphoma - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vr6ljs/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics Companies Mentioned: - Bristol-Myers Squibb - Johnson & Johnson - Seattle Genetics - Merck & Co - Gamida Cell - Millennium Pharmaceuticals - Novartis - Ono Pharmaceutical - Sigma-Tau - Incyte - 4SC - Dynavax Technologies - Spectrum - Affimed - Actinium - Philogen - Constellation - Stemline - Syndax - Acetylon - Rhizen - Immune For more information visit http://www.researchandmarkets.com/research/vr...n_lymphoma
DVAX: 15.90 (+14.31), JNJ: 108.59 (+0.39), MRK: 58.77 (-0.57), BMY: 58.58 (+0.26), NVS: 92.48 (+0.72)
Dynavax Announces Resignation of Dino Dina From Board of Directors
Marketwire - Tue Oct 07, 3:00PM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Dino Dina, M.D, has resigned from the Board of Directors. Dr. Dina was a director of the Company since 1997 and was the Company's Chief Executive Officer between 1998 and 2013.
DVAX: 15.90 (+14.31)
Dynavax (DVAX) Completes Enrolment for Study on Heplisav - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 4:00PM CDT
Dynavax Technologies Corporation (DVAX) announced that it completed the planned enrolment in the ongoing clinical trial, HBV-23, on experimental hepatitis B vaccine, Heplisav-B.
DVAX: 15.90 (+14.31), JAZZ: 171.91 (+1.11), GSK: 45.20 (+0.29), PCRX: 88.00 (+1.98)
Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
DVAX: 15.90 (+14.31), HSKA: 16.01 (+0.11), GILD: 108.21 (+1.76), ILMN: 188.95 (+2.60)
Dynavax concludes enrollment of Phase 3 Study of adult hepatitis B vaccine HEPLISAV-B
M2 - Mon Sep 22, 6:24AM CDT
Biopharmaceutical company Dynavax Technologies (NASDAQ
VAX) said on Monday that it has completed the planned enrollment of more than 8,250 adults, including over 1,100 diabetic subjects, under its ongoing phase 3 clinical trial of HEPLISAV-B at 40 sites in the US. DVAX: 15.90 (+14.31)
Dynavax Completes Enrollment of Phase 3 Study of HEPLISAV-B(TM)
Marketwire - Mon Sep 22, 5:00AM CDT
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced completion of planned enrollment in the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. More than 8,250 adults, including over 1,100 diabetic subjects, have been enrolled at 40 sites in the U.S.
DVAX: 15.90 (+14.31)
Analyst Scanner on Biotech Equities - Prana Biotechnology, CytRx, Insmed, Dynavax Technologies, and Vertex Pharma
PR Newswire - Thu Sep 11, 8:15AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.25, up 0.67%, with the index gaining 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), CytRx Corporation (NASDAQ: CYTR), Insmed Inc. (NASDAQ: INSM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research on these five companies can be accessed at:
DVAX: 15.90 (+14.31), INSM: 14.01 (-0.12), VRTX: 116.64 (+0.71), CYTR: 2.78 (-0.09), PRAN: 1.73 (-0.01)
(0)
(0)Scroll down for more posts ▼